Definitive chemoradiotherapy and consolidation durvalumab for locally advanced non-small cell lung cancer: A multicenter retrospective study

Definitive chemoradiotherapy and consolidation durvalumab for locally advanced non-small cell lung cancer: A multicenter retrospective study - Definitive chemoradiotherapy and consolidation durvalumab for locally advanced NSCLC: A multicenter retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041483

Enrollment

100

Registered

2020-08-20

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All non-small cell lung cancer patients who initiated curative-intent concurrent chemoradiotherapy (Radiotherapy start date between July 2018 and July 2019).

Exclusion criteria

Exclusion criteria: Patients who received concurrent durvalumab, had received anti-PD-1 or PD-L1 inhibitors, or had received chest irradiation except whole breast irradiation for breast cancer.

Design outcomes

Primary

Measure	Time frame
Incidence and risk factors of symptomatic radiation pneumonitis	—

Secondary

Measure	Time frame
Overall survival, Progression-free survival, Failure pattern, Incidence of other severe toxicities, Proportion of patients who receive durvalumab after definitive chemoradiotherapy	—

Countries

Japan

Contacts

Public ContactNoriko Kishi

Graduate School of Medicine, Kyoto University Department of Radiation Oncology and Image-Applied Therapy

kishin@kuhp.kyoto-u.ac.jp075-751-3762

Outcome results